ase II ROMULUS data for the Anti-79b in NHL (ASCO on May 31. ) should provide another leg to Roche's growth strategy for the Rituxan franchise, and Kadcyla data in 1st line Breast Cancer from the MARIANNE trial in 2H'14 should cement growth for the HER 2 franchise. With these catalysts to come we reite